U.S. Machinery Stock News

NYSE:AJG
NYSE:AJGInsurance

Arthur J. Gallagher (AJG) Margin Compression Tests Bullish Growth And Premium Valuation Narratives

Arthur J. Gallagher (AJG) has wrapped up FY 2025 with fourth quarter revenue of US$3.6b and basic EPS of US$0.58, alongside net income of US$151m. This puts the spotlight on how this year’s figures line up against recent history. The company has seen quarterly revenue move from US$2.5b and basic EPS of US$1.14 in Q4 2024 to US$3.6b and US$0.58 in Q4 2025. Trailing twelve month revenue came in at US$13.9b with basic EPS of US$5.74. With trailing net profit margins at 10.7% versus 13.4% a year...
NYSE:KGS
NYSE:KGSEnergy Services

Kodiak Gas Services (KGS) Is Up 5.0% After Third Straight Annual Dividend Raise Has The Bull Case Changed?

Kodiak Gas Services, Inc. recently declared a US$0.49 per-share cash dividend for the fourth quarter of 2025, payable on February 20, 2026 to shareholders of record as of February 13, 2026, while its subsidiary approved a matching distribution per unit. This marks the third consecutive year of dividend increases and underlines the company’s emphasis on a steady capital-return program to shareholders. We’ll now examine how Kodiak’s ongoing dividend growth and capital-return focus shape its...
NYSE:TDOC
NYSE:TDOCHealthcare Services

A Look At Teladoc Health’s Valuation As Medicare Telehealth Policy And Options Activity Drive Uncertainty

Medicare’s plan to roll back broad telehealth coverage starting January 31, 2026 has pushed Teladoc Health (TDOC) into the spotlight, as investors weigh regulatory risk alongside a sharp pickup in bullish options trading. See our latest analysis for Teladoc Health. The Medicare headlines and analyst concerns have landed on a stock that was already under pressure, with a 7 day share price return of a 13.9% decline and a 1 year total shareholder return of a 46.36% decline. Recent options...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

C.H. Robinson (CHRW) Earnings Rebound Of 26.1% Tests Premium Valuation Narrative

C.H. Robinson Worldwide (CHRW) closed out FY 2025 with Q4 revenue of US$3,912.6 million and basic EPS of US$1.14, while trailing twelve month figures show revenue of US$16.2 billion and EPS of US$4.88 alongside earnings growth of 26.1% over the past year. Over recent periods, the company has seen quarterly revenue range from US$4,046.7 million to US$4,184.7 million and EPS move between US$1.12 and US$1.36, with that one year earnings growth and a net profit margin rising from 2.6% to 3.6%...
NasdaqGS:TCBK
NasdaqGS:TCBKBanks

Will Earnings Growth and a Fresh Buyback Plan Change TriCo Bancshares' (TCBK) Investment Narrative

TriCo Bancshares recently reported its fourth quarter and full-year 2025 results, with net interest income of US$92.23 million in the quarter and full-year net income of US$121.56 million, alongside higher diluted earnings per share from continuing operations versus the prior year. On the same day, the Board authorized a new buyback plan for up to 2,000,000 shares after completing a prior repurchase of 1,885,076 shares, underscoring ongoing use of excess capital to return cash to...
NYSE:CUBE
NYSE:CUBESpecialized REITs

Is CubeSmart (CUBE) Pricing Look Interesting After Recent Self Storage REIT Reassessment

If you are wondering whether CubeSmart is offering good value at around US$37.53 per share, you are not alone. This article is built to unpack what that price might really mean. The stock has had mixed recent returns, with a 1.9% decline over the last 7 days, a 4.1% gain over the last 30 days, a 6.0% gain year to date, and a 5.2% decline over the last year, while sitting on a 31.7% gain across 5 years. Recent news coverage has focused on CubeSmart as part of broader self storage and real...
NYSE:DLX
NYSE:DLXCommercial Services

Deluxe (DLX) Earnings Growth And 4% Net Margin Challenge Debt Risk Concerns

Deluxe (DLX) has just wrapped up FY 2025 with fourth quarter revenue of US$535.3 million and basic EPS of US$0.33, underpinned by trailing twelve month revenue of about US$2.1 billion and EPS of US$1.87. Over the past year, the company has seen revenue move from US$520.5 million and EPS of US$0.28 in Q4 2024 to US$535.3 million and US$0.33 in Q4 2025, while full year trailing net income reached US$85.2 million, suggesting firmer margins around the edges of the business. For investors watching...
NasdaqGS:VEON
NasdaqGS:VEONWireless Telecom

VEON Growth Story Links Uzbekistan Digital Push And Kyivstar Listing Potential

VEON (NasdaqGS:VEON) is expanding its digital and cybersecurity operations in Uzbekistan with a new network operations center and the launch of BuildX, a software development and AI company. The company is also preparing a U.S. public offering of shares in its Ukrainian subsidiary Kyivstar, following preliminary results that indicate substantial annual growth under challenging geopolitical conditions. Together, these steps mark a material shift in VEON's regional footprint and could...
NYSE:IBM
NYSE:IBMIT

IBM (IBM) Margin Expansion To 15.7% Tests Cautious Earnings Narratives

International Business Machines (IBM) closed out FY 2025 with fourth quarter revenue of US$19.7b and basic EPS of US$5.96, while trailing twelve month EPS came in at US$11.34 alongside net income from continuing operations of US$10.57b. Over recent quarters the company has seen revenue move from US$17.6b in Q4 2024 to US$14.5b in Q1 2025, US$17.0b in Q2 2025 and US$16.3b in Q3 2025, with basic EPS ranging from US$1.14 to US$5.96 across the same stretch, highlighting a story in which changes...
NasdaqGS:PDD
NasdaqGS:PDDMultiline Retail

PDD Holdings Faces 2026 Regulatory Probes And Shifting Growth Outlook

PDD Holdings (NasdaqGS:PDD) is facing heightened regulatory scrutiny in China in 2026, as authorities continue sector wide probes. The company is caught up in broader investigations into internet platforms, including food delivery services and anti monopoly actions. Recent analyst commentary has flagged regulatory risk as a key issue for PDD Holdings and the wider Chinese internet sector. PDD Holdings, the owner of discount ecommerce platform Pinduoduo and global site Temu, now sits in the...
NasdaqGS:IMSR
NasdaqGS:IMSRConstruction

Terrestrial Energy DOE Agreement Puts TEFLA And IMSR Momentum In Focus

Terrestrial Energy, ticker NasdaqGS:IMSR, has executed an Other Transaction Authority agreement with the U.S. Department of Energy for Project TEFLA. The TEFLA project focuses on producing IMSR Fuel Salt and advancing domestic nuclear fuel capabilities for next generation reactors. This OTA framework is intended to support the commercial readiness of Terrestrial Energy's IMSR plants and deepen its collaboration with the DOE. Terrestrial Energy enters this agreement with the DOE as its...
NYSE:HLI
NYSE:HLICapital Markets

Houlihan Lokey Q3 Earnings Growth Outpaces History And Tests Premium P/E Narrative

Houlihan Lokey (HLI) reported a busy quarter, with Q3 2026 revenue of US$717.1 million and basic EPS of US$1.75, supported by trailing 12 month EPS of US$6.73 and net income of US$447.8 million on revenue of US$2.6 billion. Over recent quarters the company’s revenue has increased from US$574.9 million and EPS of US$1.42 in Q2 2025 to US$717.1 million and EPS of US$1.75 in Q3 2026. Over the same period, trailing 12 month EPS rose from US$5.15 to US$6.73 and net income from US$334.4 million to...
NYSE:LW
NYSE:LWFood

Is There Now An Opportunity In Lamb Weston Holdings (LW) After Multi‑Year Share Price Weakness

If you are wondering whether Lamb Weston Holdings is attractively priced today, it helps to step back and look at what the recent share performance and fundamentals are really telling you about value. The stock last closed at US$45.96, with returns of 4.2% over the past 7 days, 9.6% over 30 days, 8.7% year to date, but a 22.9% decline over 1 year and a 49.7% decline over 3 years. This can change how investors think about its risk and return profile. Recent coverage of Lamb Weston has focused...
NYSE:SMG
NYSE:SMGChemicals

Has Scotts Miracle-Gro (SMG) Finally Found A Reasonable Entry Point After Recent Rebound?

For investors wondering if Scotts Miracle-Gro at around US$65 a share still offers value, or if the easy money has already been made, this article is designed to address that question directly. The stock has recently posted returns of 5.0% over 7 days, 13.4% over 30 days and 10.1% year to date. However, the past 1 year, 3 year and 5 year returns of 4.8%, 11.5% and 67.1% declines present a different side of the story. These mixed returns reflect a period in which investors continue to...
NYSE:GEF
NYSE:GEFPackaging

Greif Uses Low Leverage And Timberland Sale To Fuel Buybacks

Greif (NYSE:GEF) approved a new $300 million share repurchase authorization. The company reported leverage at historically low levels after recent debt reduction efforts. Greif plans to sell a timberland portfolio, with proceeds expected to be used for further debt reduction. Greif, a global producer of industrial packaging and related services, operates at the intersection of manufacturing, logistics, and materials handling, areas that often track broader industrial activity. For...
NasdaqGS:STNE
NasdaqGS:STNEDiversified Financial

How Diverging Quant Models and Analyst Views on Earnings Will Impact StoneCo (STNE) Investors

In recent weeks, StoneCo has drawn attention as analysts highlighted expectations for year-over-year earnings growth of over 28% ahead of its March 2, 2026 results, even as it currently carries a Zacks Rank of #4 (Sell) and trades at a discount to its industry on a forward P/E basis. An interesting aspect is that, despite this cautious quantitative ranking, major houses such as UBS and Goldman Sachs continue to reiterate positive views on StoneCo’s business prospects, underscoring a clear...
NasdaqGS:ITRI
NasdaqGS:ITRIElectronic

Is It Time To Reconsider Itron (ITRI) After Recent Share Price Pullback?

If you are wondering whether Itron is fairly priced or offering value right now, you are not alone. The starting point is to understand what the recent share performance is really telling you. The stock last closed at US$100.19, with returns of 0.5% over the past week, 6.3% over the past month, 6.1% year to date, and a 6.8% decline over the past year. The 3 year return sits at 67.3% and the 5 year return at 1.7%. Recent coverage of Itron has focused on its role in providing technology for...
NasdaqGS:CSX
NasdaqGS:CSXTransportation

Is It Time To Reassess CSX (CSX) After Its Recent Share Price Strength?

If you are looking at CSX and wondering whether the current share price offers good value, the key question is how that price compares with what the business might reasonably be worth. CSX shares last closed at US$37.87, with returns of 5.8% over the past week, 4.0% over the past month, 4.4% year to date, 17.1% over 1 year, 21.2% over 3 years and 37.4% over 5 years, which puts recent moves in the context of a longer track record. Recent market attention on CSX has been shaped by ongoing...
NYSE:LRN
NYSE:LRNConsumer Services

Stride (LRN) Margin Improvement Challenges Slowing Earnings Growth Narrative

Stride (LRN) has just posted Q2 2026 results with revenue of US$631.3 million and basic EPS of US$2.31, while trailing twelve month revenue sits at about US$2.5 billion and EPS at US$7.39. Over recent quarters, revenue has moved from US$587.2 million and EPS of US$2.24 in Q2 2025 to US$631.3 million and EPS of US$2.31 in Q2 2026. The trailing net profit margin is 12.7% compared to 12.3% a year earlier, which points to slightly firmer profitability. Taken together, these figures present a...
NYSE:BLCO
NYSE:BLCOMedical Equipment

Is Bausch + Lomb (BLCO) Attractively Priced After Recent Mixed Share Price Performance

If you are wondering whether Bausch + Lomb shares offer good value at today's price, it helps to start by looking at what the market has been willing to pay for them recently and how that lines up with the fundamentals we can see. The stock closed at US$16.85 most recently, with a 2.0% decline over the last week, a 1.8% decline over the last month, a 1.6% gain year to date, and a 4.5% decline over the past year. Together, these figures give you a mixed picture of how sentiment has shifted...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Is Biogen (BIIB) Pricing Reflect Its Cash Flow Value After Mixed Long Term Returns

If you are wondering whether Biogen's current share price offers good value or if you might be paying too much for its future potential, this article walks through what the numbers are actually saying. Biogen shares closed at US$176.18, with returns of 2.7% over the last 7 days, 0.1% over 30 days, a 0.9% decline year to date, a 22.4% return over 1 year, a 37.9% decline over 3 years and a 33.5% decline over 5 years. This gives a mixed picture for investors weighing recent momentum against...
NYSE:FHN
NYSE:FHNBanks

Is It Time To Reassess First Horizon (FHN) After Its Recent Share Price Climb?

If you are wondering whether First Horizon's current share price lines up with its underlying worth, you are not alone, and that is exactly what this article will unpack. The stock most recently closed at US$24.42, with returns of 1.2% year to date and 14.5% over the last year. Over the past 5 years it shows a 91.2% return, with a 7 day move of a 0.9% decline and a 30 day return of 2.1%. Recent coverage around First Horizon has focused on its position within the US regional banking sector...
NYSE:CRS
NYSE:CRSAerospace & Defense

Carpenter Technology (CRS) Margin Expansion Challenges Cautious Narratives In Q2 2026 Earnings

Carpenter Technology (CRS) opened Q2 2026 with total revenue of US$728 million, basic EPS of US$2.10 and net income excluding extra items of US$105.3 million. This put fresh numbers on a year in which trailing twelve month EPS reached US$8.67 on revenue of US$2.9 billion and net income of US$434.7 million. Over the past year, the company has seen quarterly revenue move from US$676.9 million in Q2 2025 to US$728 million in Q2 2026, while basic EPS stepped up from US$1.67 to US$2.10 and...
NYSEAM:CATX
NYSEAM:CATXBiotechs

Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans

Perspective Therapeutics recently reported updated interim data from its ongoing Phase 1/2a trial of lead radiopharmaceutical candidate VMT-α-NET, indicating sustained anti-tumor activity, and issued a business update outlining clinical priorities and manufacturing expansion plans. This combination of early clinical signals and investment in production capacity highlights how the company is positioning VMT-α-NET as a core asset in its radiopharmaceutical pipeline. We’ll now examine how the...